Teladoc Health (NYSE:TDOC) Stock Price Down 4.3% Following Analyst Downgrade

Shares of Teladoc Health, Inc. (NYSE:TDOCGet Free Report) dropped 4.3% during mid-day trading on Wednesday after Evercore ISI lowered their price target on the stock from $14.00 to $10.00. Evercore ISI currently has an in-line rating on the stock. Teladoc Health traded as low as $8.76 and last traded at $8.76. Approximately 1,706,745 shares were traded during trading, a decline of 67% from the average daily volume of 5,105,919 shares. The stock had previously closed at $9.15.

TDOC has been the topic of several other research reports. Oppenheimer decreased their price target on shares of Teladoc Health from $26.00 to $21.00 and set an “outperform” rating on the stock in a research note on Friday, April 26th. Barclays cut their price target on shares of Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, April 26th. TD Cowen dropped their target price on shares of Teladoc Health from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Friday, April 26th. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teladoc Health in a research note on Friday, April 26th. Thirteen investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $17.97.

Read Our Latest Research Report on Teladoc Health

Insider Activity at Teladoc Health

In other news, COO Michael Willem Waters sold 5,793 shares of Teladoc Health stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total value of $73,513.17. Following the sale, the chief operating officer now owns 64,881 shares in the company, valued at $823,339.89. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Michael Willem Waters sold 5,793 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total value of $73,513.17. Following the transaction, the chief operating officer now directly owns 64,881 shares of the company’s stock, valued at $823,339.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen L. Daniel sold 9,834 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $11.90, for a total transaction of $117,024.60. Following the completion of the transaction, the director now directly owns 36,995 shares in the company, valued at $440,240.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,592 shares of company stock worth $397,064. 0.95% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently bought and sold shares of TDOC. ICA Group Wealth Management LLC purchased a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $28,000. Hexagon Capital Partners LLC grew its holdings in Teladoc Health by 204.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after acquiring an additional 1,065 shares in the last quarter. RIA Advisory Group LLC acquired a new position in Teladoc Health during the 4th quarter worth approximately $36,000. GAMMA Investing LLC purchased a new position in shares of Teladoc Health in the 4th quarter valued at $41,000. Finally, Principal Securities Inc. purchased a new position in shares of Teladoc Health in the 4th quarter valued at $45,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Trading Down 3.7 %

The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.74 and a current ratio of 3.82. The company’s 50-day simple moving average is $11.01 and its 200-day simple moving average is $15.14.

Teladoc Health (NYSE:TDOCGet Free Report) last released its earnings results on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.90%. The firm had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. During the same quarter last year, the business posted ($0.37) EPS. The firm’s revenue was up 2.7% on a year-over-year basis. On average, research analysts forecast that Teladoc Health, Inc. will post -1.05 EPS for the current year.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Further Reading

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.